Simulations Plus, Inc. (SLP)
NASDAQ: SLP · Real-Time Price · USD
18.20
+0.06 (0.33%)
At close: Jun 26, 2026, 4:00 PM EDT
18.04
-0.16 (-0.88%)
After-hours: Jun 26, 2026, 7:43 PM EDT
Simulations Plus Revenue
Simulations Plus had revenue of $24.29M in the quarter ending February 28, 2026, with 8.29% growth. This brings the company's revenue in the last twelve months to $80.54M, up 2.51% year-over-year. In the fiscal year ending August 31, 2025, Simulations Plus had annual revenue of $79.18M with 13.09% growth.
Revenue (ttm)
$80.54M
Revenue Growth
+2.51%
P/S Ratio
4.57
Revenue / Employee
$378,099
Employees
213
Market Cap
367.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 79.18M | 9.17M | 13.09% |
| Aug 31, 2024 | 70.01M | 10.44M | 17.52% |
| Aug 31, 2023 | 59.58M | 5.67M | 10.52% |
| Aug 31, 2022 | 53.91M | 7.44M | 16.01% |
| Aug 31, 2021 | 46.47M | 4.88M | 11.73% |
| Aug 31, 2020 | 41.59M | 7.62M | 22.43% |
| Aug 31, 2019 | 33.97M | 4.30M | 14.51% |
| Aug 31, 2018 | 29.67M | 5.53M | 22.90% |
| Aug 31, 2017 | 24.14M | 4.17M | 20.86% |
| Aug 31, 2016 | 19.97M | 1.66M | 9.05% |
| Aug 31, 2015 | 18.31M | 6.85M | 59.80% |
| Aug 31, 2014 | 11.46M | 1.39M | 13.80% |
| Aug 31, 2013 | 10.07M | 622.19K | 6.58% |
| Aug 31, 2012 | 9.45M | 709.87K | 8.12% |
| Aug 31, 2011 | 8.74M | -1.97M | -18.42% |
| Aug 31, 2010 | 10.71M | 1.57M | 17.16% |
| Aug 31, 2009 | 9.14M | 175.30K | 1.95% |
| Aug 31, 2008 | 8.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evolent Health | 1.89B |
| Claritev | 978.76M |
| Phreesia | 495.59M |
| TruBridge | 345.90M |
| HealthStream | 311.78M |
| Weave Communications | 248.72M |
| LifeMD | 193.33M |
| NRC Health | 138.64M |
SLP News
- 12 hours ago - Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel - GlobeNewsWire
- 2 days ago - Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel - Business Wire
- 3 days ago - Simulations Plus advances agentic drug development with NVIDIA BioNeMet Agent - TheFly
- 3 days ago - Simulations Plus Transcript: Status update - Transcripts
- 3 days ago - Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit - Business Wire
- 8 days ago - Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP - Business Wire
- 8 days ago - Simulations Plus downgraded to Hold from Buy at Craig-Hallum - TheFly
- 9 days ago - Simulations Plus downgraded to Market Perform from Outperform at William Blair - TheFly